- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Keymed Biosciences Inc (2162)
The Keymed Biosciences share price today is 65.35, view HK 2162 stock exchange data. Track the latest Keymed Biosciences share price with real-time updates on 2162 stock performance including market cap, day range, 52-week range and dividend yield. Access 2162 charts, earnings dates and analyst estimates to support your investment decisions.
65.35
+2.50(+3.98%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
61.90
66.80
52 wk Range
44.45
81.85
2162 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
61.9066.80
52 wk Range
44.4581.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2162 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
92.35
Upside
+41.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 92.35
(+41.31% Upside)
Earnings
Latest Release
25-09-2025
EPS / Forecast
-0.30 / --
Revenue / Forecast
498.75M / --
Compare 2162 to Peers and Sector
Metrics to compare | 2162 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2162PeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.7x | −8.0x | −0.4x | |
PEG Ratio | −9.72 | 0.05 | 0.00 | |
Price/Book | 5.8x | 3.5x | 2.6x | |
Price / LTM Sales | 22.4x | 9.6x | 3.0x | |
Upside (Analyst Target) | 51.2% | 50.5% | 56.2% | |
Fair Value Upside | Unlock | 4.5% | 8.9% | Unlock |
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study; and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial. It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma; CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia; CM383, an Aß protofibrils antibody in Phase Ib clinical study; and CM559, a N3pG Aß antibody in Phase I clinical study. In addition, the company is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study; CM326, a TSLP antibody; CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody; and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody. It has an out-licence agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Keymed Biosciences (2162) Share Price Today?
The Keymed Biosciences share price today is 65.35.
What is the current Keymed Biosciences (2162) share price and day range?
As of 26-06-2026, the Keymed Biosciences share price is 65.35, with a previous close of 62.85. The share price has ranged from 61.90 to 66.80 today, while the 52-week range spans from 44.45 to 81.85.
What Is the Keymed Biosciences Market Cap?
As of today, Keymed Biosciences market cap is 18.52B.
What Is the Keymed Biosciences (2162) Share Price Target?
The average 12-month share price target for Keymed Biosciences is 92.35, with a high estimate of 102.8418385 and a low estimate of 84.4902661. 11 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +41.31% Upside potential.
What Is Keymed Biosciences's Earnings Per Share (TTM)?
The Keymed Biosciences EPS (TTM) is -1.91.
From a Technical Analysis Perspective, Is 2162 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Keymed Biosciences Trade On?
Keymed Biosciences is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Keymed Biosciences?
The stock symbol for Keymed Biosciences is "2162."
How Many Times Has Keymed Biosciences Stock Split?
Keymed Biosciences has split 0 times.
How Many Employees Does Keymed Biosciences Have?
Keymed Biosciences has 1625 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.